| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/06/2010 | EP1409018B1 Stable lyophilized pharmaceutical formulation the igg antibody daclizumab |
| 01/06/2010 | EP1005361B1 USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
| 01/06/2010 | CN101619057A N-substituted piperidine derivatives as serotonin receptor agents |
| 01/06/2010 | CN100577633C CaSR antagonist |
| 01/06/2010 | CN100577206C Controlled release composition and method of producing the same |
| 01/06/2010 | CN100577175C Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| 01/06/2010 | CN100577170C Application of pyrazolopyrimidine Src family tyrosine kinase inhibitor in preparing medicament for curing myocardial infarction |
| 01/06/2010 | CN100577167C Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating disease related to dysfunction of peripheral benzodiazepin receptors |
| 01/06/2010 | CN100577163C Compounds effecting glucokinase |
| 01/06/2010 | CN100577162C Substituted oxazolidinones for combinational therapy |
| 01/06/2010 | CN100577144C Topical formulation for prevention and treatment of acne |
| 01/05/2010 | US7642404 Transgenic plants with controlled distribution of a trait to progeny |
| 01/05/2010 | US7642362 Compounds as semaphorin inhibitors |
| 01/05/2010 | US7642358 Antidiabetic agents; modulate insulin drug resistance |
| 01/05/2010 | US7642354 Polycyclic pyrazines as potassium ion channel modulators |
| 01/05/2010 | US7642351 2,4-Pyrimidinediamine compounds and their uses |
| 01/05/2010 | US7642286 Stable pharmaceutical compositions containing pravastatin |
| 01/05/2010 | US7642283 modulating the activity of the mitochrondrial permeability transition pore complex comprising exposing the complex to a compound such as 6-bromo-3-methylene-chroman-4-one |
| 01/05/2010 | US7642276 N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; rheumatoid arthritis |
| 01/05/2010 | US7642243 Administering C-type natriuretic peptide, guanyl cyclase (GC-B)-activating peptide |
| 01/05/2010 | US7642051 Induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (also called adenine nucleotide translocase or ADP/ATP carrier) |
| 01/05/2010 | US7641643 Methods and compositions to treat myocardial conditions |
| 01/05/2010 | CA2545999C 1,2-di(cyclic)substituted benzene compounds |
| 01/05/2010 | CA2473503C Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 01/05/2010 | CA2449098C Pharmaceutical compositions for the coordinated delivery of nsaids |
| 01/05/2010 | CA2426457C Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 01/05/2010 | CA2405796C Methods and compositions for modulating alpha adrenergic receptor activity |
| 01/05/2010 | CA2392081C Pharmaceutically active isoindoline derivatives |
| 01/05/2010 | CA2383769C Indole derivatives |
| 01/05/2010 | CA2368583C New medicament compositions based on anticholinergically-effective compounds and .beta.-mimetics |
| 01/05/2010 | CA2349475C Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells |
| 01/05/2010 | CA2318192C .beta.2-adrenergic receptor agonists |
| 01/05/2010 | CA2300480C Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| 01/05/2010 | CA2185397C Arylalkyl-diazinones |
| 12/31/2009 | US20090328240 Genetically modified mice as predictors of immune response |
| 12/31/2009 | US20090328239 Blood vessel imaging and uses therefor |
| 12/31/2009 | US20090326647 Medical devices having fluorocarbon polymer coatings |
| 12/31/2009 | US20090326645 Methods Of Application Of Coatings Composed Of Hydrophobic, High Glass Transition Polymers With Tunable Drug Release Rates |
| 12/31/2009 | US20090326248 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly; preferred compound is picropodophyllin |
| 12/31/2009 | US20090326239 Fermentative preparation process for and crystal forms of cytostatics |
| 12/31/2009 | US20090326073 Protection of normal cells |
| 12/31/2009 | US20090326058 CaSR Antagonist |
| 12/31/2009 | US20090326052 Promoters exhibiting endothelial cell specificity and methods of using same |
| 12/31/2009 | US20090326047 Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| 12/31/2009 | US20090326038 Method for treating a immunology-related disease |
| 12/31/2009 | US20090326033 Carvedilol |
| 12/31/2009 | US20090326026 Tricyclic Compounds Useful as Angiotensin II Agonists |
| 12/31/2009 | US20090325982 Phosphodiesterase 4 inhibitors |
| 12/31/2009 | US20090325962 Tyrosine derivative |
| 12/31/2009 | US20090325950 Benzoxazine derivatives and uses thereof |
| 12/31/2009 | US20090325930 Selective estrogen receptor modulator |
| 12/31/2009 | US20090325890 Use of galactose c-glycoside derivatives as protective agent and/or gama delta t lymphocyte activator |
| 12/31/2009 | US20090325861 Dry wound dressing and drug delivery system |
| 12/31/2009 | US20090324758 Plant extract mixtures and their uses |
| 12/31/2009 | US20090324744 Effective Antitumor Treatments |
| 12/31/2009 | US20090324729 Use of solid carrier particles to improve the processability of a pharmaceutical agent |
| 12/31/2009 | US20090324714 Dual adhesive technology |
| 12/31/2009 | US20090324692 Polyurethane Elastomers |
| 12/31/2009 | US20090324683 Controlled release tissue graft combination biomaterials |
| 12/31/2009 | US20090324599 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 12/31/2009 | US20090324572 Methods and compositions for the treatment of symptoms of williams syndrome |
| 12/31/2009 | US20090324571 Use of bacterial amylases in feed for bovine animals |
| 12/30/2009 | WO2009157575A1 Skin preparation for external use, whitening agent, anti-aging agent, and antioxidant |
| 12/30/2009 | WO2009157515A1 Pharmaceutical compositions |
| 12/30/2009 | WO2009157505A1 Telomerase inhibitor |
| 12/30/2009 | WO2009157399A1 Sulfonamide compound or salt thereof |
| 12/30/2009 | WO2009157196A1 Amide compound |
| 12/30/2009 | WO2009157083A1 Method of bioassaying yokkansan |
| 12/30/2009 | WO2009156481A1 Pegylated bnp |
| 12/30/2009 | WO2009156099A1 6-substituted isoquinolines and isoquinolinones |
| 12/30/2009 | WO2009062118A3 Modulation of protein trafficking |
| 12/30/2009 | EP2138580A1 Vector for gene therapy |
| 12/30/2009 | EP2138496A1 Antitumoral analogs of lamellarins |
| 12/30/2009 | EP2138489A1 Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same |
| 12/30/2009 | EP2138482A1 Bicyclic heterocyclic compound |
| 12/30/2009 | EP2138170A2 Prevention and Treatment of Oxidative Stress Disorders by compounds which elevate intracellular levels of glutathione or Phase II Detoxification Enzymes |
| 12/30/2009 | EP2136832A1 Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
| 12/30/2009 | EP2136780A1 Use of ranolazine for the treatment of cardiovascular diseases |
| 12/30/2009 | EP1763343B1 Calcium trifluoroacetate for preparing antiangiogenetic medicaments |
| 12/30/2009 | EP1558577B1 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors |
| 12/30/2009 | EP1509597B1 Method for isolating hair follicle mesenchymal stem cells |
| 12/30/2009 | EP1490047B1 Certain pharmaceutically useful substituted aminoalkyl heterocycles |
| 12/30/2009 | EP1487444B1 Use of pyridyl amides as inhibitors of angiogenesis |
| 12/30/2009 | EP1448567B1 Method for the preparation of hexahydro-furo 2,3-b furan-3-ol |
| 12/30/2009 | EP1448565B1 ADENOSINE A2a RECEPTOR ANTAGONISTS |
| 12/30/2009 | EP1430019B1 Sphingolipids |
| 12/30/2009 | EP1409482B1 Dye-sulfenates for dual phototherapy |
| 12/30/2009 | EP1307108B1 Oil/fat composition |
| 12/30/2009 | CN101613688A Von willebrand factor (vWF)-cleaving protease |
| 12/30/2009 | CN101613321A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| 12/30/2009 | CN101613310A Method of preparing amine stereoisomers |
| 12/30/2009 | CN100575497C Preparation of microbial oil containing polyunsaturated fatty acids |
| 12/30/2009 | CN100575482C Novel cytokine zcytor17 ligand |
| 12/30/2009 | CN100575345C Pyridone derivative having affinity for cannabinoid 2-type receptor |
| 12/30/2009 | CN100574804C A composition for treating gastrointestinal disorder |
| 12/30/2009 | CN100574780C Compositions against inflammatory processes |
| 12/30/2009 | CN100574769C Nerve growth factor production inhibitor and external preparation for skin, cosmetic, quasi medicine, itch prophylactic and therapeutic agent and atopic dermatitis therapeutic agent |
| 12/30/2009 | CN100574743C 抗老化剂 Anti-aging agents |
| 12/30/2009 | CN100574630C Low-salinity autumn and winter cultivation ecological bait for litopenaeus vannamei and its preparation method |
| 12/30/2009 | CN100574628C Orally taken health product for eliminating fatigue of racing pigeon |